The Tsetis Pharmaceutical Group (OFET) received a prestigious honorary distinction at the PRIX GALIEN 2023 awards, held on April 5, 2023, at the Athens Concert Hall. OFET was recognized by the Prix Galien as the “Honored Company of Pharmaceutical Innovation” for its contributions to innovation and the Greek economy. The honorary distinction was presented to the President and CEO of OFET, Julia Tseti, by the Minister of Labor & Social Affairs, Kostis Hatzidakis.
A legacy of Excellence & Innovation
In her acceptance speech, Julia Tseti—Pharmacist MSc, Honorary PhD in Pharmacy (NKUA), Secretary General of the SEV Board, and President of the UN Global Compact Network Hellas—highlighted the values that have guided the Group throughout its long-standing journey:
“The Tsetis Group is synonymous with innovation, responsible entrepreneurship, sustainable development, excellence, equal opportunities in employment and leadership, a gender-neutral work environment, and gender equality. We embrace excellence, and this philosophy is fully adopted by our 600+ employees.
The OFET Group’s pharmaceutical industries, UNI-PHARMA and InterMed, are internationally recognized as official suppliers of the United Nations, UNICEF, and the World Health Organization (WHO). Recently, we were also honored as Most Sustainable Companies and certified as a Top Employers through rigorous industry assessments.
Over the past decade, we have invested more than €120 million, while in the period 2019-2021 alone, investments exceeded €50 million. These funds were allocated to the complete renovation of UNI-PHARMA’s historic first factory on the Athens-Lamia National Road and the establishment of UniHerbo, a new industrial unit that will leverage Greece’s rich biodiversity.
Between 2018 and 2021, the Group self-funded 37 research proposals, 20 of which were scholarships awarded through the NPO KLEON TSETIS Foundation. This continuous and long-term investment in innovation has resulted in over 100 historic patents being awarded to the Group. Currently, we hold 50 national patents and 9 European patents, with 6 of these submitted for approval in nearly 60 countries.
Greece is home to remarkable basic research, and businesses must support it to ensure that young scientists remain in the country. We know that only through innovation and strategic alliances with the scientific and research community can fresh ideas emerge and smart startups flourish. These companies, driven by innovation, will enhance patient quality of life and contribute to social progress. We believe in research and the new generation, and we place our trust in young researchers because they are the ones who will bring real change to Greece”.
